Health Digest on MSN1y
The Jardiance Commercial Explained: Drug Uses, Side Effects, And More
The Food and Drug Administration approved Jardiance (empagliflozin) as a once-daily oral tablet to treat type 2 diabetes in ...
pharmaphorum10mon
Jardiance doesn’t cut it in post-heart attack trial
The EMPACT-MI trial found that giving Boehringer Ingelheim and Eli Lilly’s SGLT2 drug Jardiance (empagliflozin) within 14 days of an acute myocardial infarction (AMI) reduced the risk of a ...
pharmaphorum4d
FDA fast-tracks Lilly/Boehringer’s Jardiance for heart failure
Eli Lilly and Boehringer Ingelheim’s Jardiance was the first diabetes drug to lower the risk of cardiovascular disease in a clinical trial, and is now on course to be the first to have a chronic ...
Healio1d
Semaglutide may raise risk for form of optic neuropathy in adults with type 2 diabetes
Adults with type 2 diabetes may have a higher risk for developing nonarteritic anterior ischemic optic neuropathy while using ...
Hosted on MSN16d
Health Rounds: Ingested plastic particles head for the brain
In pigs receiving anthracyclines, the researchers administered a 20 mg daily dose of the SGLT2 inhibitor empagliflozin, sold as Jardiance by Boehringer Ingelheim. Empagliflozin increases the heart ...
FierceBiotech11d
Boehringer widens fibrosis drug's approval path after boosting lung function in 2nd phase 3 trial
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
Boehringer’s zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer
Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...
BioSpace11d
Boehringer Ingelheim’s Lung Fibrosis Drug Scores Second Late-Stage Win
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
TCTMD1mon
Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study
Compared with empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly), dapagliflozin produced a similar impact on MI/stroke risk but was associated with an increased risk of heart failure (HF) ...
emjreviews.com2d
FDA fast-tracks Boehringer’s NSCLC drug review
The FDA has granted Priority Review to Boehringer Ingelheim's new drug application for its non-small cell lung cancer therapy ...
TCTMD21d
Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations
Merck), empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly), and insulin aspart (Fiasp and NovoLog; Novo Nordisk). Similarly, total spending for all 10 drugs increased from $3.5 to $27.5 billion ...